The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.

The court filing follows a CNBC investigation that detailed how these third-party vendors have spread across U.S.

Context for Gilead Sciences stock today Gilead Sciences (GILD) is in focus for investors after recent share price moves, with ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

Gilead Sciences advances global biopharmaceutical research as companies within the nasdaq 100 index shape healthcare ...

Gilead Sciences promoted Keeley Wettan to EVP, general counsel, legal and compliance. She will join the senior leadership ...

Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...

Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior day's close.

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences ...

Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six ...

As we enter 2026, U.S. equities are expected to enter a phase marked by several complexities following the outsized gains in ...

Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...